DEDAGROUP-STEALTH
14.5.2020 08:03:12 CEST | Business Wire | Press release
Dedagroup Stealth, the tech company behind more than 60% of Italy’s best-known global fashion brands, has acquired Zedonk, the company relied on by more than 650 small fashion businesses.
Until now, smaller brands and start-ups had no access to a single, integrated solution for managing the entire product life cycle, from initial design and production, right through to multichannel distribution in retail, wholesale, marketplaces and social commerce channels, and in addition they had no access to an Enterprise Resource Planning (ERP) technology to support rapid international growth. The acquisition of Zedonk by Dedagroup Stealth fills this market gap.
Dedagroup Stealth is one of only a handful of international companies with a wide range of software solutions for the efficient and flexible management of all the production and distribution processes for fashion products across multiple channels, which has given it leadership among large and medium-sized brands.
Now, with Zedonk, Dedagroup Stealth will be a unique partner for smaller fashion companies, from the very beginning of their growth trajectory right through to international expansion.
Zedonk enables brands in their emerging phase as well as those who are established, but want to accelerate their digital transformation journeys. Its solutions include design and production management, stock inventory, purchase orders, style management as well as customer and supplier relations, with all data managed and protected in the Cloud.
As well as complementary technologies, the two companies now have a significant footprint in the UK through new headquarters in London where Dedagroup Stealth consultants already on the ground will join the Zedonk team.
Marcia Lazar, Co-founder of Zedonk , said: "We join the Dedagroup Stealth family with great enthusiasm. For us, it is the ideal strategic partner to continue on our ambitious development path. We are truly satisfied with this global operation, which has the clear objective of bringing to the fashion sector an offer that can accompany any brand in every phase of its life, from the launch to the intermediate development phase up to maturity, supporting it in the definition of processes and strategies.”
Mimmo Solida, CEO of Dedagroup Stealth , added: “For too long, many brands have struggled to find an integrated solution that helps them manage their entire supply chain. It has long been our ambition to find a partner that can support designers, small brands and fashion start-ups as they grow, with a range of solutions that support business critical focuses of fashion retailers, from supply chain to sales, that allow for internationalisation. This acquisition will bring new value to the market and, at the same time, will strongly support our expansion strategy geographically and as a business, whilst completing our product portfolio to support fashion brands from entrepreneurial start-ups to enterprise players.”
Marco Podini, Executive Chairman of Dedagroup Stealth parent company Dedagroup, commented: "I am particularly pleased by the acquisition of Zedonk because our software, which has already contributed to the growth of many important creative brands in the world, can help other small fashion companies to develop rapidly. Our support is more vital than ever now that the market has changed so drastically for companies of all sizes, made even worse in the current crisis as whole countries shut down.”
“The global fashion industry needs the right tools to capitalise on business opportunities without being overwhelmed at an organisational level. The tsunami moving from east to west, leaving behind lowered shutters and people locked indoors, will be followed by a second wave that will see everyone wanting to get back to normal. Agility, underpinned by robust digital technologies, will be the catalyst that defines business success and will fuel retail performance in markets as they reopen, starting from China. Dedagroup Stealth will be able to support brands from the very smallest up to the largest as they restart their plans for global expansion,” Podini concluded.
-ENDS-
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005645/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
